A multicenter, prospective, real-world study of oral semaglutide in adults with type 2 diabetes in Japanese clinical practice (PIONEER REAL Japan): Subgroup analyses.

AIMS: HbAand body weight were assessed across selected subgroups of adults with type 2 diabetes receiving oral semaglutide in clinical practice. METHODS: In this non-interventional study, changes in HbAand body weight to end of study (EoS) and safety were assessed by subgroup: baseline age, body mass index (BMI), type 2 diabetes duration, participants switching from dipeptidyl peptidase-4 inhibitors, and semaglutide dose at EoS. RESULTS: All subgroups experienced reductions in HbAand body weight. Younger participants had greater reductions in HbAthan older participants (-0.9, -0.7, -0.7, and -0.5 percentage points for participants aged <55, ≥55-<65, ≥65-<75, and ≥75 years, respectively [P = 0.0467]). Shorter type 2 diabetes duration and lower EoS semaglutide dose were associated with greater HbAreductions (-0.8, -0.7, and -0.6 percentage points with ≤5, >5-≤10, and >10 years' duration, respectively [P < 0.0001]; -1.2, -0.7, and -0.4 percentage points with 3, 7, and 14 mg, respectively [P < 0.0001]). Changes in HbAwere not significantly different across other subgroups. Lower EoS semaglutide dose was associated with greater body weight reductions (-3.8, -2.9, and -2.8 kg with 3, 7, and 14 mg, respectively [P < 0.0001]); body weight reductions were not significantly different across other subgroups. Adverse events were similar between subgroups, except that older subgroups experienced more events. CONCLUSIONS: HbAand body weight decreased across all subgroups, providing insights into oral semaglutide use in clinical practice for individuals with different characteristics in the real-world setting.